戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 dose (0.1, 1.0, or 10 Eq with respect to the diabody).
2 y fragments, creating bispecific antibodies (diabodies).
3 he C6ML3-9 diabody to 15-fold for the C6G98A diabody.
4 therapeutic agent: a bispecific single-chain diabody.
5 for an anti-tumor-associated glycoprotein 72 diabody.
6 trast images at 18 h for the (124)I-anti-CEA diabody.
7 ding presumably also selects for more stable diabodies.
8 ssessment of tolerability, the anti-CLDN18.2 diabody (0.34 mg/kg) did not produce obvious signs of to
9                      Early administration of diabody (0.8 mg/kg) caused a twofold decrease in brain l
10           Prophylactic administration of the diabody (0.8 mg/kg) in a thromboplastin-induced model of
11 odistribution of the 18F-fluorobenzyl-T84.66 diabody (18F-FB-T84.66 diabody) was evaluated in athymic
12  Similar values were obtained for the (124)I-diabody (3.95 at 4 h and 10.93 at 18 h).
13  (89)Zr-desferrioxamine-labeled anti-CD8 cys-diabody ((89)Zr-malDFO-169 cDb) for noninvasive immuno-P
14 d anti-carcinoembryonic antigen (CEA) T84.66 diabody, a genetically engineered noncovalent dimer of s
15                            The anti-PSCA cys-diabody A2 was site-specifically conjugated with either
16 e anti-prostate stem cell antigen (PSCA) cys-diabody A2, and subsequently radiolabeled by click chemi
17  model of cerebral ischemia and reperfusion, diabody administration (0.8 mg/kg, 1 hour postocclusion)
18                                              Diabodies also elicited biased or differential activatio
19                                       The Di-diabody also inherited the biological properties from bo
20 ibody or with 3.1 MBq (85 microCi) of (124)I-diabody and imaged at 4 and 18 h by PET.
21 he structure of a complex between a bivalent diabody and its antigen, influenza neuraminidase, has be
22  uptake levels than did the smaller formats (diabody and scFv).
23 r N-terminal cysteines of antibodies in IgG, diabody and small immunoprotein (SIP) formats that yield
24 kidney uptake and retention of non-PEGylated diabody and that the two have similarly high tumor uptak
25 h cells, the molecule was expressed in scFv, diabody and triabody formats in a number of cell lines t
26 ere n indicates the number of TCO groups per diabody) and radiolabeled tetrazine to optimize the TCO
27 ication grade (0, 1.8, or 4.7 TCO groups per diabody) and the (177)Lu-tetrazine dose (0.1, 1.0, or 10
28  as 1 h after injection of the 18F-FB-T84.66 diabody, and only a background level of activity accumul
29 Db9C2 diabody (anti-group I) and the Db4C1op diabody (anti-AahII), the latter being modified to facil
30            The mixture consists of the Db9C2 diabody (anti-group I) and the Db4C1op diabody (anti-Aah
31                                              Diabodies are capable of substantial accumulation in tum
32                                              Diabodies are noncovalent dimers of single-chain antibod
33                                         Such diabodies are produced in a cell-free protein expression
34           With a Mr of approximately 55,000, diabodies are rapidly cleared from the circulation, resu
35 atial proximity of the two antigen arms in a diabody arrangement essential to the tumor killing activ
36 ooctene (TCO)-functionalized TAG72 targeting diabody, AVP04-07, and a low-molecular-weight radiolabel
37 d these pMHC were cloned into a single-chain diabody backbone (scDb) sequence, such that one fragment
38                                              Diabody binding kinetics were determined by surface plas
39                                       The Di-diabody binds to both EGFR and IGFR and effectively bloc
40  athymic mice with both the chemical and the diabody bispecific proteins.
41 ssociate and reassociate to form a dimer, or diabody, but in which symmetric back-to-back contacts be
42 in the kidney, the use of radiometal-labeled diabodies can be problematic for both imaging and therap
43                            The 18F-FB-T84.66 diabody can be used for high-contrast small-animal PET i
44  in vivo, we generated anti-CD4 and -CD8 cys-diabodies (cDbs) derived from the parental antibody hybr
45                          The PEG27 and PEG12 diabody conjugates also demonstrated low kidney uptake w
46 beled with (64)Cu, the DOTA-PEG12 and -PEG27 diabody conjugates gave high-contrast PET images of colo
47 9 F(ab')(2) and a fully humanized bispecific diabody construct (BS1.5H), expressed in Escherichia col
48                                 In fact, the diabody constructed from the lowest affinity scFv exhibi
49 These noncognate B cells, decorated with the diabody, could then stimulate the more rare Id-specific
50 nsistent with the maximum possible number of diabody cross-links.
51 Ds were conjugated to an engineered anti-CD8 diabody (Cys-diabody) for in vivo molecular imaging of C
52                                  We utilized diabodies (DA) as surrogate ligands in a prototypical di
53 ti-prostate-specific membrane antigen (PSMA) diabody (Db) and minibody (Mb), were compared with intac
54 tion of an Id vaccine, we engineered a small diabody (Db) molecule containing both a B-cell-targeting
55 nhibitor against TAFI and PAI-1 (heterodimer diabody, Db-TCK26D6x33H1F7) in several mouse models of t
56 te protein ligands for TPO-R, in the form of diabodies (DBs), that homodimerize TPO-R on the cell sur
57 isingly, the differences in affinity between diabodies did not result in differences in quantitative
58                      In contrast to tPA, the diabody did not increase accumulative bleeding.
59                        When using the BS1.5H diabody for pretargeting, tumor-to-blood, tumor-to-liver
60 gated to an engineered anti-CD8 diabody (Cys-diabody) for in vivo molecular imaging of CD8+ cytotoxic
61  for the HER2 receptor tyrosine kinase (C6.5 diabody) for its ability to function as a PET radiotrace
62 uman CD3 mAb v9 in a clinically investigated diabody format known as Dual-Affinity Re-Targeting (DART
63                                         This diabody format, when combined with the power of phage di
64 e synthesized B11-nanobody, B11-scFv and B11-diabody fragments from the full-length anti-PD-L1 B11 Ig
65 ycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the kidney uptake and retenti
66    Based on the results, [(64)Cu]Cu-NOTA-B11-diabody has potential to be used as a PET imaging probe
67 reviously shown that targeting of EMP2 using diabodies in endometrial cancer resulted in a reduction
68                                              Diabody-induced signaling amplitudes varied from full to
69                                Non-signaling diabodies inhibited proliferation of erythroid precursor
70 labeled tetrazine was injected at 47 h after diabody injection, and mice were euthanized 3 h later.
71       We also show that the presence of both diabodies is necessary for the animals to survive.
72                             Furthermore, the diabody is a stronger inhibitor than its parent antibodi
73   The present work evaluated the minibody or diabody labeled with (124)I, for imaging tumor-bearing m
74                                        Phage diabody libraries enable screening or selection of the b
75              Peptide epitopes present in the diabody linker augmented the response by activating CD4(
76                                    PEGylated diabodies may be a valuable platform for delivery of rad
77                                        These diabodies may have therapeutic applications requiring th
78                                              Diabodies may provide a useful approach to the structure
79                              Such bispecific diabodies may provide an attractive alternative to monoc
80                                        Thus, diabodies may represent an effective molecular structure
81 dual receptor blockade with the bifunctional diabody may prove to be a more efficient approach in inh
82       Engineered antibody fragments, such as diabodies, minibodies, and single-chain Fv (scFv) -Fc, h
83                 Here, we report the use of a diabody mixture in which the molar ratio matches the cha
84 e intraperitoneal injection of 30 mug of the diabody mixture protected almost all the mice exposed to
85          18F labeling of the anti-CEA T84.66 diabody (molecular mass, 55 kDa) was achieved with N-suc
86 association rate constants obtained for each diabody molecule were similar to that of the parental (c
87                                    Antitumor diabody molecules are noncovalent single-chain Fv dimers
88 dicate that genetically engineered antitumor diabody molecules can be used as effective vehicles for
89           Here, we have constructed bivalent diabody molecules from three affinity mutants of the hum
90 detailed to create repertoires of bispecific diabody molecules with variability on one or both of the
91 gment [scFv]-C(H)3 dimer, 80 kDa) and T84.66 diabody (noncovalent dimer of scFv, 55 kDa) exhibit phar
92 was increased fivefold compared to a control diabody of the same molecular weight.
93                    Delayed administration of diabody or tPA had no effect on lesion size, whereas the
94 om 33% to 88%, and immunoreactivity was 42% (diabody) or >90% (minibody).
95 tly reduced by blocking with the non-labeled diabody (p < 0.001).
96                    Tumor accumulation of the diabody peaked at 3 h, reaching a much lower level (3.7
97 s currently conducting time-dependent (124)I diabody PET and necropsy comparative studies with larger
98 applied to in vivo (124)I anti-HER2/neu C6.5 diabody PET data and compared with necropsy biodistribut
99                                   The (124)I diabody PET image of a mouse with a tumor xenograft was
100 udy, we utilized (89)Zr-labeled anti-CD8 cys-diabody-PET to provide proof-of-concept to detect CD8(+)
101 enewal assays we find that partial agonistic diabodies preserved the stem-like properties of cultured
102               The addition of PEG3400 to the diabody reduced kidney uptake to a level (approximately
103                              The 18F-labeled diabody represents a new class of tumor-specific probes
104 ingle-chain Fv and a bispecific single-chain diabody, respectively.
105  300 microCi (300 microg) 90Y-CHX-A"-C6.5K-A diabody resulted in only a minor delay in the growth of
106                                          The diabody retained the capacity to bind both KDR and Flt-1
107    We therefore engineered a bispecific scFv diabody (scDb) combining affinities for both c-erbB2 and
108 he present study, we report two single-chain diabodies (scDbs) that target the HIV-1 envelope protein
109 re injected with (89)Zr-labeled anti-CD8 cys-diabody seven days post oHSV administration and imaged w
110     Out of the three antibody fragments, B11-diabody showed higher nM affinity towards PD-L1 antigen
111                            The 18F-FB-T84.66 diabody showed rapid and high tumor uptake and fast clea
112  PET images using (124)I-labeled minibody or diabody showed specific localization to the CEA-positive
113  Eq of (177)Lu-tetrazine with respect to the diabody showed the most promising biodistribution.
114                                     The IgG, diabody, single-chain variable domain (scFv), and novel
115                  The scFv used to create the diabodies span a 133-fold range of affinity for the same
116 an chimeric IgG1 and IgA1 and a single-chain diabody specific for the C-terminal 19-kDa region of Pla
117                              Finally, the Di-diabody strongly inhibited the growth of two different h
118 tegy based on a covalently linked bispecific diabody structure that we term dual-affinity re-targetin
119 ers that is consistent with a domain-swapped diabody structure.
120 ion is discussed in terms of a new model for diabody structures, in which the V(H) and V(L) domains i
121  150 microCi (200 microg) 90Y-CHX-A"-C6.5K-A diabody substantially inhibits the growth rates of estab
122       Anti-hCLDN18.2 ADC, CD3-bispecific and diabody, targeting a protein sequence conserved in rat,
123 re we constructed a recombinant bifunctional diabody that is capable of blocking both Flt-1 and KDR f
124 0 (t1/2, 64 hours) conjugated to the C6.5K-A diabody that specifically targets the HER2/neu human tum
125 ing from only 3-fold for that of the C6ML3-9 diabody to 15-fold for the C6G98A diabody.
126 e the use of a bispecific antibody fragment (diabody) to recruit the whole spectrum of antibody effec
127 gments (Fab, scFv)) and engineered variants (diabodies, triabodies, minibodies and single-domain anti
128 ical cross-linking methods and as bispecific diabodies using recombinant DNA technologies.
129 ant human IgG-like bispecific antibody, a Di-diabody, using the variable regions from two antagonisti
130                                          One diabody was able to recruit C1q, resulting in efficient
131 rebral artery occlusion, the efficacy of the diabody was compared to the standard thrombolytic treatm
132                               One arm of the diabody was directed against the target antigen, and the
133                                          The diabody was expressed in Escherichia coli and purified b
134                      At 24 h, 3-37-fold more diabody was retained in tumor compared with the parental
135 g from 18F-SFB, and the tracer 18F-FB-T84.66 diabody was synthesized with a specific activity of 1.83
136 F-fluorobenzyl-T84.66 diabody (18F-FB-T84.66 diabody) was evaluated in athymic nude mice bearing subc
137                               The bispecific diabodies were able to recruit complement, induce mononu
138                                     AVP04-07 diabodies were functionalized with TCO tags, and in vitr
139 ion rate constants obtained for the bivalent diabodies were up to 15-fold slower.
140 re rapidly cleared from circulation, and the diabody, which accumulated in the tumor, may be more sui
141 neuraminidase tetramers cross-linked by four diabodies with 422 point symmetry.
142 chain fragment variable clones to generate a diabody with mutant Y75L was successfully performed and
143 size, whereas the combined administration of diabody with tPA caused a 1.7-fold decrease in lesion si

 
Page Top